Sign In
Buy BLUE
$4.97
+0 (+0%)
At Close: Aug 29, 2025
bluebird bio - The Good, The Bad And The Ugly
04:44am, Friday, 13'th Aug 2021
bluebird bio - The Good, The Bad And The Ugly
bluebird bio: Throwing My Thesis In The Can And Starting Over From Scratch
01:37am, Wednesday, 11'th Aug 2021
bluebird bio: Throwing My Thesis In The Can And Starting Over From Scratch
bluebird (BLUE) Q2 Loss Wider Than Expected, Revenues Fall Y/Y
02:39pm, Monday, 09'th Aug 2021
bluebird (BLUE) reports a wider-than-expected loss in second-quarter 2021 and also misses revenue estimates. Shares down in pre-market trading as FDA places clinical hold eli-cel.
SVB Leerink Says 'We Were Wrong,' Slashes Bluebird Bio Price Target
01:41pm, Monday, 09'th Aug 2021
After the FDA placed a clinical hold on Bluebird Bio Inc's (NASDAQ:BLUE) cerebral adrenoleukodystrophy gene therapy, SVB Leerink downgraded the stock to Market Perform from Outperform. Analyst M
Why Bluebird Bio Stock Is Crashing Today
12:38pm, Monday, 09'th Aug 2021
The drugmaker had a double whammy of bad news.
Bluebird Bio, Inc. (BLUE) CEO Nick Leschly on Q2 2021 Results - Earnings Call Transcript
12:31pm, Monday, 09'th Aug 2021
Bluebird Bio, Inc. (BLUE) CEO Nick Leschly on Q2 2021 Results - Earnings Call Transcript
Bluebird Bio (BLUE) Reports Q2 Loss, Misses Revenue Estimates
09:19am, Monday, 09'th Aug 2021
Bluebird (BLUE) delivered earnings and revenue surprises of -9.82% and -55.08%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: bluebird bio Q2 Earnings
07:25am, Monday, 09'th Aug 2021
Shares of bluebird bio (NASDAQ:BLUE) moved higher by 0.9% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 852.78% year over year to ($3.43),
Is This Small-Cap Biotech a Buy After Its Second Approved Gene Therapy?
07:21am, Tuesday, 03'rd Aug 2021
After receiving yet another treatment approval from regulators, Bluebird Bio looks like a bargain.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BLUE--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the European Commission (EC) has granted marketing authorization of SKYSONA™ (elivaldogene autotem
Should Investors Hold Out Hope for bluebird bio and Merck Spinoff Organon?
09:01am, Saturday, 10'th Jul 2021
Neither healthcare stock has performed well so far this year.
Bluebird Bio To Resume Zynteglo Gene Therapy Marketing In Europe After Positive Recommendation From PRAC
10:48am, Friday, 09'th Jul 2021
European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has concluded that the benefit-risk of Bluebird Bio Inc's (NASDAQ: BLUE) Zynteglo (betibeglogene autotemcel gene
BLUE Brings Back Treatment From Marketing Suspension
10:36am, Friday, 09'th Jul 2021
The shares of bluebird bio Inc (NASDAQ:BLUE) are higher today, on news that the biotech company is lifting its voluntary marketing suspension of its gene therapy treatment, Zynteglo.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BLUE--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has conclud
CRISPR: 4 Emerging Players
09:06am, Wednesday, 30'th Jun 2021
CRISPR can be utilized ubiquitously as a search and replace tool allowing scientists to identify DNA sequences. The potential uses of CRISPR are numerous across a large variety of fields including agr
